Can protein kinase C inhibition and vitamin E prevent the development of diabetic vascular complications?

Diabetes Research and Clinical Practice

Volumn 45, Issue 2-3, 1999, Pages 169-182

  Bursell, Sven Erik ^a   King, George L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Diabetic vascular complications; Protein kinase C; Vitamin E

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM); ALPHA TOCOPHEROL; ANTIOXIDANT; DIACYLGLYCEROL; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR;

ARTICLE; BLOOD FLOW; BLOOD VESSEL PERMEABILITY; CLINICAL TRIAL; DIABETIC ANGIOPATHY; DRUG EFFECT; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HUMAN; HYPERGLYCEMIA; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY BLOOD VESSEL; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; RETINA BLOOD VESSEL;

ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; HUMANS; HYPERGLYCEMIA; ISOENZYMES; MUSCLE, SMOOTH, VASCULAR; PROTEIN KINASE C; VITAMIN E;

EID: 0032852869     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(99)00047-9     Document Type: Article

References (128)

1. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. New Engl. J. Med. 318:1988;1315-1321.
2. Vlassara H. Advanced glycation end products and atherosclerosis. Ann. Med. 28:1996;419-426.
3. Schmidt A.M., Hori O., Cao R., Yan S.D., Brett J., Wautier J.L., Ogawa S., Kuwabara K., Matsumoto M., Stern D. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes. 45:1996;S77-S80.
4. Kaiser N., Sasson S., Feener E.P., Boukobza-Vardi N., Higashi S., Moller D.E., Davidheiser S., Przybylski R.J., King G.L. Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes. 42:1993;80-89.
5. Greene D., Lattimer S.A., Sima A.A.F. Sorbitol, phosphoinositides and sodium-potassium-ATPase in the pathogenesis of diabetic complications. New Engl. J. Med. 316:1987;599-606.
6. Williamson J.R., Chang K., Frangos M., Hasan K.S., Ido Y., Kawamura T., Nyengaard J.R., Van den Enden M., Kilo C., Tilton R.G. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes. 42:1993;801-813.
7. King G.L., Ishii H., Koya D. Diabetic vascular dysfunctions: a model of excessive activation of protein kinase C. Kidney Int. 52:1997;S77-S85.
8. Derubertis F.R., Craven P.A. Activation of protein kinase C in glomerular cells in diabetes. Mechanisms and potential link to the pathogenesis of diabetic glomerulopathy. Diabetes. 43:1994;1-8.
9. Sharma K., Ziyadeh F.N. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-b as a key modulator. Diabetes. 44:1995;1139-1146.
10. Baynes J.W., Thorpe S.R. The role of oxidative stress in diabetic complications. Curr. Opin. Endocrinol. 3:1996;277-284.
11. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 258:1992;607-614.
12. Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB. 9:1995;484-496.
13. Liscovitch M., Cantley L.C. Lipid second messengers. Cell. 77:1994;329-334.
14. Nakanishi H., Brewer K.A., Exton J.H. Activation of the zeta isozyme of protein kinase C by phosphatidylinositol 3, 4, 5-trisphosphate. J. Biol. Chem. 268:1993;13-16.
15. Chang K.Y., Szallasi Z., Acs P., Raizada V., Wolfe P.C., Fewtrell C., Blurnberg P.M., Rivera J. Functional effects of overexpression of protein kinase C-α, -β, -δ, -ε, and -η in the mast cell line RBL-2H3. J. Immunol. 159:1997;2624-2632.
16. Shiba T., Inoguchi T., Sportsman J.R., Heath W., Bursell S., King G.L. Correlation of diacylglycerol and protein kinase C activity in rat retina to retinal circulation. Am. J. Physiol. 265:1993;E783-E793.
17. Inoguchi T., Battan R., Handler E., Sportsman J.R., Heath W., King G.L. Preferential elevation of protein kinase C isoform βII and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc. Natl. Acad. Sci. USA. 89:1992;11059-11063.
18. Craven P.A., Davidson C.M., DeRubertis F.R. Increase in diacylglycerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipids. Diabetes. 39:1990;667-674.
19. Ishii H., Jirousek M.R., Koya D., Takagi C., Xia P., Clermont A., Bursell S.-E., Kern T.S., Ballas L.M., Heath W.F., Stramm L.E., Feener E.P., King G.L. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science. 272:1996;728-731.
20. Considine R.V., Nyce M.R., Allen L.E., Morales L.M., Triester S., Serrano J., Colberg J., Lanza-Jacoby S., Caro J.F. Protein kinase C is increased in the liver of humans and rats with non-insulin-dependent diabetes mellitus: an alteration not due to hyperglycemia. J. Clin. Invest. 95:1995;2938-2944.
21. Saha A.K., Kurowski T.G., Colca J.R., Ruderman N.B. Lipid abnormalities in tissues of the KKAy mouse: effects of pioglitazone on malonyl-CoA and diacylglycerol. Am. J. Physiol. 267:1994;E95-E101.
22. Xia P., Inoguchi T., Kern T.S., Engerman R.L., Oates P.J., King G.L. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes. 43:1994;1122-1129.
23. Craven P.A., DeRubertis F.R. Protein kinase C is activated in glomeruli from streptozotocin diabetic rats. J. Clin. Invest. 83:1989;1667-1675.
24. Yasanare K., Kahno M., Kano H., Yokokawa K., Horio T., Yoshikawa J. Possible involvement of phospholipase and protein kinase C in vascular growth induced by elevated glucose concentration. Hypertension. 28:1996;159-168.
25. Inoguchi T., Pu X., Kunisaki M., Higashi S., Feener E.P., King G.L. Insulin's effect on protein kinase C and diacylglycerol induced by diabetes and glucose in vascular tissues. Am. J. Physiol. 267:1994;369-379.
26. Berne C. The metabolism of lipids in mouse pancreatic islets. The biosynthesis of triacylglycerol and phospholipids. Biochem. J. 152:1975;667-673.
27. Dunlop M.E., Larkins R.G. Pancreatic islets synthesize phospholipids de novo from glucose via acyl-dihydroxyacetone phosphate. Biochem. Biophys. Res. Commun. 132:1985;467-473.
28. Brindley D.N., Sturton R.G. Phosphatidate metabolism and its relation to triacylglycerol biosynthesis. Hawthorne J.N., Ansel G.B. Phospholipids. 1982;179-207 Elsevier, New York.
29. Holub B.J., Kuksis A. Metabolism of molecular species of diacylglycerol phospholipids. Adv. Lipid Res. 16:1986;1-125.
30. Ido Y., McHowat J., Chang K.C., Arrogori-Martelli E., Orfaliam Z., Kilo C., Corr P.B., Williamson J.R. Neural dysfunction and metabolic imbalances in diabetic rats. Prevention by acetyl-L carritine. Diabetes. 43:1994;1469-1477.
31. Ayo S.H., Radnik R., Garoni J.A., Troyer D.A., Kreisberg J.I. High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures. Am. J. Physiol. 261:1991;571-577.
32. Kunisaki M., Bursell S.-E., Umeda F., Nawata H., King G.L. Normalization of diacylglycerol-protein kinase C activation by vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose levels. Diabetes. 43:1994;1372-1377.
33. Koya D., Jirousek M.R., Lin Y.-W., Ishii H., Kuboki K., King G.L. Characteristics of protein kinase C β isoform activation on the gene expression of transforming growth factor β, extracellular matrix components and prostanoids in the glomeruli of diabetic rats. J. Clin. Invest. 100:1997;115-126.
34. Kikkawa R., Haneda M., Uzu T., Koya D., Sugimoto T., Shigeta Y. Translocation of protein kinase α and ζ in rat glomerular mesangial cells cultured under high glucose conditions. Diabetologia. 37:1994;838-841.
35. Bursell S.-E., Clermont A.C., Kinsley B.T., Simonson D.C., Aiello L.M., Wolpert H.A. Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 37:1996;886-897.
36. Feke G.T., Buzney S.M., Ogasawara H., Fujio N., Goger D.G., Spack N.P., Gabbay K.H. Retinal circulatory abnormalities in type 1 diabetes. Invest. Ophthalmol. Vis. Sci. 35:1994;2968-2975.
37. Clermont A.C., Aiello L.P., Mori F., Aiello L.M., Bursell S.E. Vascular endothelial growth factor and severity of non-proliferative diabetic retinopathy mediate retinal hemodynamics in vivo: a potential role for vascular endothelial growth factor in the progression of non-proliferative diabetic retinopathy. Am. J. Ophthalmol. 124:1997;433-446.
38. Konno S., Feke G.T., Yoshida A., Fujio N., Goger D.G., Buzney S.M. Retinal blood flow changes in Type I diabetes: a long term follow-up study. Invest. Ophthamol. Vis. Sci. 37:1996;1140-1148.
39. Small K.W., Stefansson E., Hatchell D. Retinal blood flow in normal and diabetic dogs. Invest. Ophthalmol. Vis. Sci. 28:1987;672-675.
40. Clerrnont A.C., Brittis M., Shiba T., McGovern T., King G.L., Bursell S.-E. Normalization of retinal blood flow in diabetic rats with primary intervention using insulin pumps. Invest. Ophthalmol. Vis. Sci. 35:1994;981-990.
41. Miyamoto K., Ogura Y., Nishiwaki H., Matsuda N., Honda Y., Kato S., Ishida H., Seino Y. Evaluation of retinal microcirculatory alterations in the Goto-Kakizaki rat. Invest. Ophthalmol. Vis. Sci. 37:1996;898-905.
42. Takagi C., King G.L., Clermont A.C., Cumrnins D.R., Takagi H., Bursell S.E. Reversal of abnormal retinal hemodynamics in diabetic rats by acarbose, an α-glucosidase inhibitor. Curr. Eye Res. 14:1995;741-749.
43. Higashi S., Clermont A.C., Dhir V., Bursell S.E. Reversibility of retinal flow abnormalities is disease-duration dependent in diabetic rats. Diabetes. 47:1998;653659.
44. Kohner E.M. Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy. Diabetes. 44:1995;603-607.
45. Tesfayes S., Malik R., Ward J.D. Vascular factors in diabetic neuropathy. Diabetologia. 37:1994;847-851.
46. + ATPase defects in diabetic rats. Diabetes. 46(suppl. 1):1997;31A-0121.
47. Takagi C., Bursell S.-E., Lin Y.-W., Takagi H., Duh E., Jiang Z., Clermont A.C., King G.L. Regulation of retinal hemodynamics in diabetic rats by increased expression and action of endothelin-1. Invest. Ophthalmol. Vis. Sci. 37:1996;2504-2518.
48. Takagi C., King G.L., Takagi H., Lin Y.-W., Clermont A.C., Bursell S.E. Endothelin-1 action via endothelin receptors is a primary mechanism modulating retinal circulatory response to hyperoxia. Invest. Ophthalmol. Vis. Sci. 37:1996;2099-9109.
49. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., Park J.E., Nguyen H.V., Aiello L.M., Ferrara N., King G.L. Vascular endothelial growth factor in ocular fluids of patients with diabetic retinopathy and other retinal disorders. New. Engl. J. Med. 331:1994;1480-1487.
50. Williams B., Gallachen B., Patel H., Orme C. Glucose-induced protein kinase C activation regulates vasular permeability factor mRNA expression and peptide production vascular smooth muscle cells in vitro. Diabetes. 46:1997;1497-1503.
51. Ditzel J., Schwartz M. Abnormally increased glomerular filtration rates in short-term insulin treated diabetic subjects. Diabetes. 16:1967;264-267.
52. Christiansen J.S., Gammelgaard J., Frandsen M., Parving H.H. Increased kidney size. glomerular filtration rate and renal plasma flow in short-term insulin-dependent diabetes. Diabetologia. 20:1981;451-456.
53. Hostetter T.H., Troy J.L., Brenner B.M. Glomerular hemodynamics in experimental diabetes mellitus. Kidney. Int. 19:1981;410-415.
54. Viberti G.C. Early functional and morphological changes in diabetic nephropathy. Clin. Nephrol. 12:1979;47-53.
55. O'Donnell M.P., Kasiske B.L., Keane W.F. Glomerular hemodynamic structural alterations in experimental diabetics mellitus. FASEB. 2:1988;2339-2347.
56. Anderson S., Jung F.F., Ingelfinger J.R. Renal renin-angiotensin system in diabetes: functional immunohistochemical and molecular biologica correlations. Am. J. Physiol. 265:1993;F477-F486.
57. Ruan X., Arendshorst W.J. Role of protein kinase C in angiotensin II-induced renal vasoconstriction in genetically hypertensive rats. Am. J. Physiol. 270:1996;F945-F952.
58. Craven P.A., Caines M.A., DeRubertis F.R. Sequential alterations in glomerular prostaglandin and thromboxane synthesis in diabetic rats: relationship to the hyperfiltration of early diabetes. Metabolism. 36:1987;95-103.
59. Perico N., Benigni A., Gabanelli M., Piccinelli A., Ròg M., Riva C.D., Remuzzi G. Atrial natriuretic peptide and prostacyclin synergistically mediate hyperfiltration and hyperperfusion of diabetic rats. Diabetes. 41:1992;533-538.
60. Williams B., Schrier R.W. Glucose-induced protein kinase C activity regulates arachidonic acid release and eicosanoid production by cultured glomerular mesangial cells. J. Clin. Invest. 92:1993;2889-2896.
61. 2. J. Clin. Invest. 96:1995;733-740.
62. Haneda M., Arakis I., Togaro M., Sugimoto T., Isono M., Kikkawa R. Mitogen activated protein kinase C is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes. 46:1997;847-853.
63. 2 is phosphorylated and activated by MAP kinase. Cell. 72:1993;269-278.
64. Bank N., Aynedjian H.S. Role of EDRF (nitric oxide) in diabetic renal hyperfiltration. Kidney. Int. 43:1994;1306-1312.
65. Tolins J.P., Shultz P.J., Raij L., Brown D.M., Mauer S.M. Abnormal renal hemodynamic response to reduce renal perfusion pressure in diabetic rats: role of NO. Am. J. Physiol. 265:1993;F886-F895.
66. Komers R., Allen T.J., Cooper M.E. Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes. Diabetes. 43:1994;1190-1197.
67. Sharma K., Danoff T.M., DePiero A., Ziyadeh F.N. Enhanced expression of inducible nitric oxide synthase in murine macrophages and glomerular mesangial cells by elevated glucose levels: possible mediation via protein kinase C. Biochem. Biophys. Res. Commun. 207:1995;80-88.
68. 2+/EDRF signaling are due to generation of superoxide anions. Diabetes. 45(10):1996;1386-1395.
69. Craven P.A., Studer R.K., DeRubertis F.R. Impaired nitric oxide-dependent cyclic guanosine monophosphate generation in glomeruli from diabetic rats. J. Clin. Invest. 93:1994;311-320.
70. Muniyappa R., Srinivas P.R., Ram J.L., Walsh M.F., Sowers J.R. Calcium and protein kinase C mediate high-glucose-induced inhibition of inducible nitric oxide synthase in vascular smooth muscle cells. Hypertension. 31 (1 PT2):1998;289-295.
71. Nishio E., Watanabe Y. Glucose-induced down-regulation of NO production and inducible NOS expression in cultured rat aortic vascular smooth muscle cells: role of protein kinase C. Biochem. Biophys. Res. Commmun. 229(3):1996;857-863.
72. Kamata K., Miyata N., Kasuya Y. Involvement of endothelial cells in relaxation and contraction responses of the aorta to isoproterenol in native and streptozotocin-induced diabetic rats. J. Pharmacol. Exp. Ther. 249:1989;890-894.
73. Mayhan W.G. Impairment of endothelium-dependent dilatation cerebral arterioles during diabetes mellitus. Am. J. Physiol. 256:1989;H621-H625.
74. 2. Am. J. Physiol. 257:1989;H1327-H1333.
75. McVeigh G.E., Brennan G.M., Johnston G.D., McDermott B.J., McGrath L.T., Henry W.R., Andrews J.W. Impaired endothelium-dependent and independent vasodilation in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 35:1992;771-776.
76. Tesfamariam B., Brown M.L., Cohen R.A. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J. Clin. Invest. 87:1991;1643-1648.
77. Williamson J.R., Chang K., Tilton R.G., Prater C., Jeffrey J.R., Weigel C., Sherman W.R., Eades D.M., Kilo C. Increased vascular permeability in spontaneously diabetic BB/W rats and in rats with mild versus severe streptozocin-induced diabetes. Diabetes. 36:1987;813-821.
78. Oliver J.A. Adenylate cyclase and protein kinase C mediate opposite actions on endothelial junctions. J. Cell. Physiol. 145:1990;536-542.
79. Lynch J.J., Ferro T.J., Blumenstock F.A., Brockenauer A.M., Malik A.M. Increased endothelial albumin permeability mediated by protein kinase C activation. J. Clin. Invest. 85:1990;1991-1998.
80. Wolf B.A., Williamson J.R., Easom R.A., Chang K., Sherman W.R., Turk J. Diacylglycerol accumulation and microvascular abnormalities induced by elevated glucose levels. J. Clin. Invest. 87:1991;31-38.
81. Werth D.K., Niedel J.E., Pastan I. Vinculin, a cytoskeletal substrate of protein kinase C. J. Biol. Chem. 258:1983;11423-11426.
82. Stasek J.E., Patterson C.E., Garcia J.G.N. Protein kinase C phosphorylates caldesmon and vimentin and enhances albumin permeability across cultured bovine pulmonary artery endothelial cell monolayers. J. Cell. Physiol. 153:1992;62-75.
83. 1 overexpression augments phorbol ester-induced increase in endothelial permeability. J. Cell. Physiol. 166:1996;249-255.
84. Xia P., Aiello L.P., Ishii H., Jiang Z., Park D.J., Robinson G.S., Takagi H., Newsome W.P., Jirousek M.R., King G.L. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J. Clin. Invest. 98:1996;2018-2026.
85. Aiello L.P., Bursell S.E., Clermont A., Duh E., Ishii H., Takagi C., Mori F., Ciulla T.A., Ways K., Jirousek M., Smith L.E., King G.L. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes. 46:1997;1473-1480.
86. King G.L., Shiba T., Oliver J., Inoguchi T., Bursell S.-E. Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus. Ann. Rev. Med. 45:1994;179-188.
87. Winegrad A.I. Does a common mechanism induce the diverse complications of diabetes? Diabetes. 36:1987;396-406.
88. MacGregor L.C., Matschinsky F.M. Altered retinal metabolism in diabetes II: measurement of sodium-potassium ATPase and total sodium and potassium in individual retinal layers. J. Biol. Chem. 261:1986;4052-4058.
89. Williamson J.R., Kilo C. Extracellular matrix changes in diabetes mellitus. Scarpelli D.G., Migahi G. Comparative Pathobiology of Major Age-Related Diseases. 1984;269-288 Alan R. Liss, New York.
90. Lu T.T., Yan L.G., Madri J.A. Integrin engagement mediates tyrosine dephosphorylation on platelet-endothelial cell adhesion molecule 1. Proc. Natl. Acad. Sci. 93:1996;11808-11813.
91. Scheinman J.L., Fish A.J., Matas A.J., Michael A.F. The immunohistopathology of glomerular antigens. II. The glomerular basement membrane, actomyosin, and fibroblast surface antigens in normal, diseased and transplanted human kidneys. Am. J. Pathol. 90:1978;71-88.
92. Bruneval P., Foidart J.M., Nochy D., Camilleri J.P., Bariety J. Glomerular matrix proteins in nodular glomerulosclerosis in association with light chain deposition disease and diabetes mellitus. Hum. Pathol. 16:1985;477-484.
93. Studer R.K., Craven P.A., DeRubertis F.R. Role for protein kinase C in the mediation of increased fibronectin accumulation by mesangial cells grown in high-glucose medium. Diabetes. 42:1993;118-126.
94. Ayo S.H., Radnik R.A., Garoni J., Glass W.F. II, Kreisberg J.I. High glucose causes an increase in extracellular matrix proteins in cultured mesangial cells. Am. J. Pathol. 136:1990;1339-1348.
95. Ayo S.H., Radnik R.A., Glass I.I. W.F., Garoni J.A., Rampt E.R., Appling D.R., Kreisberg J.I. Increased extracellular matrix synthesis and mRNA in mesangial cells grown in high-glucose medium. Am. J. Physiol. 260:1991;F185-F191.
96. Haneda M., Kikkawa R., Horide N., Togawa M., Koya D., Kajiwara N., Ooshima A., Shigeta Y. Glucose enhances type IV collagen production in cultured rat glomerular mesangial cells. Diabetologia. 34:1991;198-200.
97. Pugliese G., Pricci F., Pugliese F., Mene P., Lenti L., Andreani D., Galli G., Casini A., Bianchi S., Rotella C.M., Mario U.D. Mechanisms of glucose-enhanced extracellular matrix accumulation in rat glomerular mesangial cells. Diabetes. 43:1994;478-490.
98. 1 (IV) transcriptional activity in a reporter mesangial cell line. Am. J. Physiol. 267:1994;F632-F638.
99. MacKay K., Striker L.J., Stauffer J.W., Doi T., Agodoa L.Y., Striker G.E. Transforming growth factor β. Murine glomerular receptors and responses of isolated glomerular cells. J. Clin. Invest. 83:1989;1160-1167.
100. Suzuki S., Ebihara I., Tomino Y., Koide H. Transcriptional activation of matrix genes by transforming growth factor β1 in mesangial cells. Exp. Nephrol. 1:1993;229-237.
101. Nakamura T., Miller D., Ruoslahti E., Border W.A. Production of extracellular matrix by glomerular epithelial cells in regulated by transforming growth factor-β1. Kidney. Int. 41:1992;1213-1221.
102. Yamamoto T., Nakamura T., Noble N.A., Ruoslahti E., Border W.A. Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc. Natl. Acad. Sci. USA. 90:1993;1814-1818.
103. Sharma K., Ziyadeh F.N. Renal hypertrophy is associated with upregulation of TGF-β1 gene expression in diabetic BB rat and NOD mouse. Am. J. Physiol. 267:1994;F1094-F1101.
104. Pankewycz O.G., Guan J.-X., Bolton W.K., Gomez A., Benedict J.F. Renal TGF-β regulation in spontaneously diabetic NOD mice with correlations in mesangial cells. Kidney. Int. 46:1994;748-758.
105. F.N. Ziyadeh, K. Sharma, M. Ericksen, G. Wolf, Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β, J. Clin. Invest.
106. Sharma K., Jin Y., Guo J., Ziyadeh F.N. Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes. 45:1996;522-530.
107. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensin converting enzyme inhibitor on diabetic nephropathy. New. Engl. J. Med. 329:1993;1456-1462.
108. Baynes J.W., Thorpe S.R. The role of oxidative stress in diabetic complications. Curr. Opin. Endocrinol. 3:1996;277-284.
109. Gingliano D., Cerellio A., Paolisso G. Diabetes mellitus, hypertension and cardiovascular disease: which role for oxidative stress. Metabolism. 44:1995;363-368.
110. Giugliano D., Cerellio A., Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes. Care. 19:1996;257-265.
111. 2 in high glucose medium. Diabetes. 44:1995;520-526.
112. Chappey O., Dosquet C., Wautier M.P., Wautier J.L. Advanced glycation end products, oxidant stress and vascular lesions. Eur. J. Clin. Invest. 27:1997;97-108.
113. Stampfer M.J., Hennekens C.H., Manson J.E., Colditz G.A., Rosner B., Willett W.C. Vitamin E consumption and the risk of coronary disease in women. New. Engl. J. Med. 328:1993;1444-1449.
114. Rimm E.B., Stampfer M.J., Ascherio A., Giovannucci E., Colditz G.A., Willett W.C. Vitamin E consumption and the risk of coronary heart disease in men. New. Engl. J. Med. 328:1993;1450-1456.
115. Heinonen O.P., Albanes D., Virtamo J. et al. Prostate cancer and supplementation with α-tocopherol and β-carotene: incidence and mortality in a controlled trial. J. Natl. Cancer. Inst. 90:1998;440-446.
116. Mares-Perlman J.A., Brady W.E., Klein R. et al. Serum antioxidants and age-related macular degeneration in a population-based case-control study. Arch. Ophthalmol. 113:1995;1518-1523.
117. Snodderly D.M. Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins. Am. J. Clin. Nutr. 62:1995;1448S-1461.
118. Berson E.L., Rosner B., Sandberg M.A. et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch. Ophthalmol. 111:1993;761-772.
119. Johnson L., Quinn G.E., Abbasi S., Gerdes J., Bowen F.W., Bhutani V. Severe retinopathy of prematurity in infants with birth weights less than 1250 grams: incidence and outcome of treatment with pharmacologic serum levels of vitamin E in addition to cryotherapy from 1985 to 1991. J. Pediatr. 127:1995;632-639.
120. Kunisaki M., Bursell S.-E., Clermont A.C., Ishii H., Ballas L.M., Jirousek M.R., Umeda F., Nawata H., King G.L. Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway. Am. J. Physiol. 269:1995;E239-E246.
121. Crabtree D.V., Snodderly D.M., Adler A.J. Retinyl palmitate in macaque retina-retinal pigment epithelium-choroid: distribution and correlation with age and vitamin E. Exp. Eye. Res. 64:1997;455-463.
122. Crabtree D.V., Adler A.J., Snodderly D.M. Radial distribution of tocopherols in rhesus monkey retina and retinal pigment epithelium-choroid. Invest. Ophthalmol. Vis. Sci. 37:1996;61-76.
123. Friedrichson T., Kalbach H.L., Buck P., van Kuijk F.J. Vitamin E in macular and peripheral tissues of the human eye. Curr. Eye. Res. 14:1995;693-701.
124. Boscoboinik D., Szewczyk A., Hensey C., Azzi A. Inhibition of cell proliferation by α-tocopherol. Role of protein kinase C. J. Biol. Chem. 266:1991;6188-6194.
125. Porte D., Schwartz M.W. Diabetes complications: why is glucose potentially toxic? Science. 272:1996;699-700.
126. Nicolucci A., Carinci F., Cavaliere D., Scorpiglione N., Belfiglio M., Labbrozzi D., Mari E., Benedetti M.M., Tognoni G., Liberati A. A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration. Diabet. Med. 13:1996;1017-1026.
127. Bursell SE, Clermont AC, Aiello LP, Aiello LM, Schlossman DK, Feener EP, Laffel L, King GL. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with Type I diabetes. Diabetes Care 1999 (in press).
128. Aiello L.P., Bursell S.E., Devries T., Alatorre C., King G.L., Ways K. Protein Kinase C β-selective inhibitor LY333531 ameliorates abnormal retinal hemodynamics in patients with diabetes. Diabetes. 48(Suppl 1):1999;A19.